HomeBest options strategy › GOSS

Best Options Strategy for GOSS

By Dennis Bosmans · Updated 2026 · 2 min read · Risk disclaimer

Looking for the best options strategy for Gossamer Bio, Inc. (GOSS)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live GOSS option chain right now, and a simple map from your view on GOSS to the strategy that fits it. Model any of them in the calculator before you trade.

About GOSS

Gossamer Bio, Inc. (GOSS) is a major company in Biotechnology. Options traders on GOSS tend to watch , since these can drive large moves in the share price.

About Gossamer Bio, Inc.

Gossamer Bio is a clinical-stage biopharmaceutical company developing targeted therapies for rare lung diseases. Its main asset is GB002, an inhaled medication that works by inhibiting multiple receptor pathways involved in disease progression. The compound targets PDGFR, CSF1 receptor, and c-KIT and is currently in Phase 3 trials for pulmonary arterial hypertension, a serious condition affecting the lungs and heart. The company operates under a license agreement with Pulmokine, Inc., which grants it rights to develop and commercialize GB002 along with backup candidate compounds.

Gossamer Bio generates revenue and value primarily through its clinical pipeline and licensing arrangements. As a clinical-stage company without approved products yet, it operates in the rare disease space where treatments address significant unmet medical needs and often command premium pricing. The company is based in San Diego and has structured its business model around partnership arrangements that help fund development costs while maintaining commercial rights to its leading therapy.

Today's top-scoring strategy for GOSS

Our engine ranks defined-risk strategies on the live GOSS chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.

Long Call Butterfly neutral
Price: $100.00Implied volatility: 32%Expiration: 2026-07-17 (30d)
ActionQtyTypeStrikePremium
BuyCALL$95$6.83
SellCALL$100$3.82
BuyCALL$105$1.87
P/L at expiry vs today At expiry Today ±1σ
$82$100$118
Max Profit
$394
Max Loss
−$106
Net Debit (cost)
$106
Prob. of Profit
33%
Breakeven(s)
$96.06, $103.94
Implied Vol (ATM)
32%
Position Greeks
Δ
0.43
Γ
−1.202
Θ
1.69
ν
−3.16
Time decay (price held)

Simulation

Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.

Win rate
33%
Mean P/L
−$2
Median
−$106
Exp. move (1σ)
9%
5th pct
−$106
25th pct
−$106
75th pct
$96
95th pct
$333
$-100$144$388
Analyze GOSS in the calculator → Share this pick ↗

Illustrative example at GOSS's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.

Implied volatility

GOSS typically trades with moderate implied volatility, broadly in line with other large-cap stocks. Implied volatility drives option prices, so it is worth checking the live chain before you trade.

Earnings & IV crush

GOSS's next earnings report is due around August 5, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.

Key figures

Market cap
$85M
Beta (vs market)
2.00
52-week range
$0.14–$3.87
Short interest
11.7% of float · 3.0 days to cover

With 11.7% of GOSS's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.

How to choose an options strategy for GOSS

Start with your outlook on GOSS, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:

Bullish

You expect GOSS to rise

Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.

Long Call → Bull Call Spread →

Bearish

You expect GOSS to fall

Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.

Long Put → Bear Put Spread →

Neutral

You expect GOSS to trade in a range

Sell an iron condor to collect premium while GOSS stays between two strikes, or write a covered call against shares you already own.

Iron Condor → Covered Call →

How we pick the best strategy

For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →

Open GOSS in the free calculator →

Frequently asked questions

What is the best options strategy for GOSS?

It depends on your outlook. Bullish traders often use a long call or bull call spread on GOSS; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.

Are GOSS options liquid enough to trade?

Gossamer Bio, Inc. (GOSS) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.

How much money do I need to trade GOSS options?

Buying a single GOSS call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.

Is this financial advice?

No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade GOSS or any security. Do your own research.

What does Gossamer Bio, Inc. do?

Gossamer Bio, Inc. (GOSS) operates in the Biotechnology industry. The "About Gossamer Bio, Inc." section above gives a fuller picture of what the company does and how it earns money.

Does Gossamer Bio, Inc. pay a dividend?

Gossamer Bio, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.

When does Gossamer Bio, Inc. next report earnings?

Gossamer Bio, Inc.'s next earnings are expected around August 5, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.

Tickers related to GOSS

Comparing GOSS with similar names can help you choose the best options strategy:

ALECAlector, Inc.STOKStoke Therapeutics, Inc.BDTXBlack Diamond Therapeutics, Inc.

Company information

Headquarters
3115 Merryfield Row, Suite 120, San Diego, CA, 92121, United States
Industry
Biotechnology
Employees
161
CEO
Mr. Faheem Hasnain
Phone
858 684 1300
Website
www.gossamerbio.com

Best Options Strategy by Ticker →

Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.